Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Finally listened to call

<< Previous

Bullboard Posts

Next >>

Comment by juniper88on Oct 14, 2022 12:30pm

146 Views

Post# 35025011

RE:RE:RE:RE:RE:RE:RE:RE:RE:Finally listened to call

You made the accusation and you want me to disprove your accusation??

Realy???

You come up with the numbers to prove your accusation that patient accrual is a problem. Until you do it is just your assumption.

There is nothing I can write to shut someone like you up.

Joemare wrote: You write "Patient accrual is a problem". Do you have any proof of this or are you just making this up like everythig else you write??

Really???

Cough up the numbers to shut me up! I want to be proven wrong all the way.....I'll be a very happy shareholder making money. I want to be proven wrong. Now, I'm loosing money........That's the issue.